Cubist Systematic Strategies LLC Purchases Shares of 21,922 Enovis Co. (NYSE:ENOV)

Cubist Systematic Strategies LLC purchased a new stake in shares of Enovis Co. (NYSE:ENOV - Free Report) during the 4th quarter, according to the company in its most recent filing with the SEC. The fund purchased 21,922 shares of the company's stock, valued at approximately $962,000.

Other large investors have also added to or reduced their stakes in the company. Aster Capital Management DIFC Ltd purchased a new stake in shares of Enovis in the fourth quarter worth about $29,000. Quadrant Capital Group LLC boosted its stake in shares of Enovis by 53.0% in the fourth quarter. Quadrant Capital Group LLC now owns 690 shares of the company's stock worth $30,000 after buying an additional 239 shares during the last quarter. UMB Bank n.a. boosted its stake in shares of Enovis by 128.2% in the fourth quarter. UMB Bank n.a. now owns 778 shares of the company's stock worth $34,000 after buying an additional 437 shares during the last quarter. Pinnacle Bancorp Inc. boosted its stake in shares of Enovis by 54.5% in the fourth quarter. Pinnacle Bancorp Inc. now owns 850 shares of the company's stock worth $37,000 after buying an additional 300 shares during the last quarter. Finally, Quarry LP boosted its stake in shares of Enovis by 506.1% in the fourth quarter. Quarry LP now owns 897 shares of the company's stock worth $39,000 after buying an additional 749 shares during the last quarter. Hedge funds and other institutional investors own 98.45% of the company's stock.

Wall Street Analysts Forecast Growth

Several brokerages have commented on ENOV. Canaccord Genuity Group dropped their price objective on Enovis from $75.00 to $70.00 and set a "buy" rating on the stock in a report on Wednesday. Needham & Company LLC dropped their price objective on Enovis from $64.00 to $57.00 and set a "buy" rating on the stock in a report on Friday, May 9th. Finally, JMP Securities dropped their price objective on Enovis from $62.00 to $55.00 and set a "market outperform" rating on the stock in a report on Friday, May 9th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $58.00.

Enovis Stock Performance

NYSE ENOV opened at $36.21 on Thursday. The company has a market cap of $2.07 billion, a PE ratio of -16.53 and a beta of 1.79. The stock's 50 day simple moving average is $35.16 and its 200-day simple moving average is $41.49. Enovis Co. has a 1-year low of $29.32 and a 1-year high of $53.84. The company has a debt-to-equity ratio of 0.40, a current ratio of 2.27 and a quick ratio of 1.12.

Enovis (NYSE:ENOV - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported $0.81 earnings per share for the quarter, beating the consensus estimate of $0.74 by $0.07. The business had revenue of $558.83 million for the quarter, compared to the consensus estimate of $558.80 million. Enovis had a positive return on equity of 4.39% and a negative net margin of 5.95%. The business's quarterly revenue was up 8.2% compared to the same quarter last year. During the same quarter last year, the business posted $0.50 earnings per share. As a group, equities research analysts anticipate that Enovis Co. will post 2.79 EPS for the current fiscal year.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.

Want to see what other hedge funds are holding ENOV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enovis Co. (NYSE:ENOV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.